Connect with us

Health

HMO Controversy: What Nigerians, hospitals need to know about health insurance

info

Published

on

Pelumi Akinboade Senior Executive Officer and Insurance Nurse 1.jpg

MTN ADVERT

A viral social media post about the use of Health Maintenance Organisations (HMOs) has sparked controversy among Nigerians and healthcare professionals over health insurance.

The post, made on X on 2 August by user @106_36_52, who identifies as a medical doctor on the platform, criticised a family who, according to him, visited a hospital after church for medical checks under their HMO plan.

“I give the federal government 24 hours to ban this thing called HMO in Nigeria. Full family, straight from church with matching Ankara. Third set only today. God abeg,” he wrote.

The post had generated more than 1.9 million views as of 12 August and was subsequently shared by blogs, attracting reactions from Nigerians and healthcare professionals.

While some Nigerians questioned why healthcare providers should be concerned about how frequently insured patients use their health plans, others argued that the reactions failed to recognise the financial and administrative pressures faced by healthcare providers and HMOs.

PT WHATSAPP CHANNEL

In this explainer, PREMIUM TIMES examines how health insurance works in Nigeria, the responsibilities of patients, healthcare providers and HMOs, and what the law says about their obligations.

How health insurance works

One of the biggest misconceptions exposed by the debate is the idea that an HMO patient is receiving free treatment.

The patient may not pay the hospital at the point of service, but that does not mean the service is free or that the provider is working for free.

Health insurance is built around pooling financial contributions to pay for healthcare when members need it. The National Health Insurance Authority (NHIA) describes social health insurance as a system in which contributions are pooled to provide a defined package of healthcare services.

Pelumi Akinboade, a senior executive officer and insurance nurse, explained that HMOs perform important administrative functions within this arrangement, including enrolment, claims management, authorisation, quality assurance and coordination between enrollees and healthcare providers.

He said providers are paid through arrangements such as capitation and fee-for-service, depending on the level and nature of care.

“Patients may not bear the bulk of their care costs out of pocket, as their respective insurance companies pay their healthcare providers directly through capitation and fee-for-service,” Mr Akinboade told PREMIUM TIMES.

A patient using an insurance plan is not asking a doctor to treat them for free. They are accessing a service that is supposed to be financed through an insurance arrangement.

Doctors’ frustration

The viral post, however, also highlights another side of the system. It is easy to dismiss a doctor’s complaint as hostility towards HMO patients.

Healthcare providers depend on HMOs to pay for services they have already provided, and problems with payments or authorisations can affect how facilities deliver care.

Mr Akinboade identified delayed payments, administrative bottlenecks, limited coverage, and disputes between providers and HMOs as factors that can contribute to delays or denials of care.

The NHIA Act 2022 specifically provides penalties for failure to remit payments to healthcare providers within the stipulated period and for failure to settle fee-for-service and other claims within the required timeframe.

The federal government has also acknowledged pressure on provider financing. In announcing revised payment rates under the national health insurance scheme, the NHIA said capitation fees had increased by more than 90 per cent, while fee-for-service payments had risen by 378 per cent.

The Coordinating Minister of Health and Social Welfare, Muhammad Pate, said the adjustment was intended to reduce the financial burden on healthcare providers and improve services for enrollees.

So while a patient’s use of their insurance should not automatically be blamed for a provider’s frustration, neither can the financial concerns of healthcare facilities be dismissed.

The law, dispute

Section 47 of the NHIA Act 2022 provides that disputes among parties under the Act should first be referred to the Authority for mediation and conciliation. The Act specifically identifies HMOs, healthcare providers, contributors, and the Authority as parties that may be involved in such disputes.

Section 48 makes it an offence to fail to remit payments to healthcare providers within the period specified in the operational guidelines, fail to settle fee-for-service or other provider claims within the stipulated period, or fail to provide care to a duly registered enrollee.

These provisions suggest that the law itself recognises the possibility of disputes over payments, claims and access to care within the health insurance system. This means the tension playing out online between patients, healthcare providers and HMOs is not simply a question of patients “overusing” their insurance.

It also raises questions about whether the obligations imposed on each party are being fulfilled.

In other words, while enrollees are expected to understand the terms of their health plans and follow the applicable procedures, healthcare providers and HMOs also have obligations under the regulatory framework governing health insurance in Nigeria.

Insured patients still have rights.

Mr Akinboade said healthcare providers must recognise this distinction. Hospitals, he said, should have trained personnel who understand health insurance and can properly guide patients through the process.

He rejected the idea that insured patients should receive a lower standard of care because they are not paying directly at the point of treatment.

“Insurance patients are not secondary patients. They own the right to quality healthcare services,” he said.

That position is consistent with the NHIA’s own statement of enrollee rights. The Authority says Nigerians covered under its programmes have the right to easy access to quality healthcare without hindrance and to be treated with respect and dignity.

The distinction is particularly important in Nigeria, where health insurance coverage remains low, and households continue to shoulder a large share of healthcare costs.

A 2025 Nigeria Health Systems and Services Profile published through the African Health Observatory Platform, with World Health Organisation (WHO) involvement, reported that out-of-pocket spending accounted for more than 75 per cent of total health expenditure and estimated that only about five per cent of Nigerians were covered by health insurance, prepayment or other risk-pooling mechanisms.

In such a system, health insurance is intended to protect households from the financial consequences of illness.

Patients also have responsibilities.

Mr Akinboade said patients also need to understand the health insurance package they have enrolled in.

Different plans have different benefits, exclusions and limitations. Enrollees therefore need to understand the services covered by their plans, the facilities available to them and the procedures for referrals and authorisations.

Patients should also know how to report problems when care is delayed or denied. Mr Akinboade advised enrollees to keep the contact details of their HMO’s customer service or quality assurance unit and escalate complaints when necessary.

Health insurance, therefore, is not simply a card presented at a hospital. It is an arrangement that creates responsibilities for patients, healthcare providers and HMOs.

What needs to change

Improving the system will require action from all sides, Mr Akinboade said.

He added that HMOs need to process claims and pay healthcare providers promptly while ensuring that referrals and authorisations do not create unnecessary barriers to care.

Healthcare providers need trained insurance desk officers who understand the terms of different plans and can communicate them clearly to patients.

Regulators also need to enforce existing rules and impose consequences where organisations fail to meet their obligations.

Meanwhile, patients need to understand their benefits, exclusions and responsibilities and use available complaint mechanisms when they encounter problems.

The NHIA Act provides a framework for resolving disputes between HMOs, healthcare providers, contributors and the Authority, including mediation and conciliation.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Nigerian drugmaker Fidson selected to manufacture generic influenza antiviral under global licence

info

Published

on

Untitled design 17.png

A Nigerian pharmaceutical company, Fidson Healthcare Plc, has been selected to develop and manufacture a generic version of baloxavir marboxil, an antiviral medicine used to treat influenza.

The selection makes Fidson one of 11 manufacturers across nine countries chosen under a voluntary licensing agreement between the Medicines Patent Pool (MPP) and Swiss pharmaceutical company Roche.

The company disclosed this in a press release signed by its media contact, Tope Akindele. The MPP, a United Nations-backed public health organisation, also announced the sublicence agreements on 25 September.

The selected manufacturers are from Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine and Vietnam. The MPP said the arrangement is intended to “diversify supply pathways for influenza treatment, support regional production, and strengthen preparedness for future outbreaks and pandemics.”

What it means for Fidson, Nigeria

The selection makes Fidson one of the manufacturers that would develop, manufacture and supply generic versions of baloxavir in 129 countries covered by the licence, subject to regulatory authorisation.

The agreement also gives selected manufacturers access to technical data, reference products for bioequivalence studies and other support to facilitate product development and regulatory approval.

PT WHATSAPP CHANNEL
Dangote Refinery AD

The MPP said it selected the manufacturers following an open Expression of Interest process and an assessment of their technical and regulatory capacities and commitment to producing quality-assured baloxavir products.

The organisation said having manufacturers in different regions would help build production capacity closer to the populations the medicines are intended to serve and strengthen the resilience of global supply.

For Nigeria, the selection places a local pharmaceutical manufacturer in a global effort to expand production of an influenza antiviral while strengthening domestic and regional pharmaceutical manufacturing capacity.

Selection strengthens Africa’s role

Fidson’s Managing Director and Chief Executive Officer, Biola Adebayo, described the selection as a validation of the company’s commitment to quality-assured pharmaceutical manufacturing and innovation.

“Being selected by the Medicines Patent Pool as a sublicensee under the Roche-MPP voluntary licensing programme for baloxavir marboxil is both an honour and a validation of Fidson’s longstanding commitment to quality-assured pharmaceutical manufacturing, innovation, and improving healthcare outcomes,” Mr Adebayo said.

He said the partnership would allow the company to contribute to efforts to strengthen regional health security and preparedness for future health emergencies.

“As an African healthcare company, we are proud to contribute to global efforts aimed at strengthening regional health security, enhancing preparedness for future health emergencies, and ensuring that life-saving medicines reach the patients who need them most,” he said.

Mr Adebayo said the partnership also demonstrated the growing role of African manufacturers in the global health ecosystem.

He said Fidson would work with Roche, the MPP and other stakeholders to support broader access to baloxavir across eligible markets.

READ ALSO: Fidson, Nigeria’s largest pharmaceutical company, delivers N3.6 billion dividend to shareholders

Part of pandemic preparedness

The announcement came as global leaders gathered in New York for the United Nations General Assembly to discuss pandemic prevention, preparedness and response.

The MPP said the licensing arrangement is designed to build manufacturing capacity before, rather than during, a health emergency.

Charles Gore, Executive Director of the MPP, said the organisation would work with the selected manufacturers on product development and regulatory approval, aiming to make quality-assured generic baloxavir available as quickly as possible.

“By combining global manufacturing capacity with regionally focused production, we are helping build a more geographically diverse and resilient supply base for the future,” Mr Gore said.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Health

Non-communicable diseases caused 74% of global deaths in 2023

info

Published

on

World Health Organisation.jpg

Non-communicable diseases (NCDs) such as heart disease, diabetes and dementia accounted for 74 per cent of global deaths in 2023, up from 58 per cent in 2000, according to the latest estimates released by the World Health Organisation (WHO).

The findings, contained in the WHO’s latest Global Health Estimates released on Friday, show that although global life expectancy has largely recovered from the disruption caused by the COVID-19 pandemic, the world’s disease burden is increasingly shifting towards chronic illnesses and mental health conditions.

According to the report, global life expectancy reached 73.3 years in 2023, almost returning to the 73.4 years recorded in 2019 before the pandemic. However, healthy life expectancy, which measures the number of years people live in good health, recovered more slowly, reaching 62.8 years in 2023, still 0.4 years below its pre-pandemic level.

The WHO noted that eight of the world’s 10 leading causes of death were NCDs in 2023, highlighting a long-term global shift away from communicable diseases.

Cardiovascular diseases remain leading killer

The report identified cardiovascular diseases as the leading cause of death and disease burden worldwide.

It said ischaemic heart disease alone caused approximately 9.5 million deaths and 210 million disability-adjusted life years (DALYs) in 2023. DALYs measure years of healthy life lost due to illness, disability or premature death.

PT WHATSAPP CHANNEL
Dangote Refinery AD

While many parts of the world have made significant progress in reducing the burden of ischaemic heart disease since 2000, the WHO reported rising individual-level risks in the Western Pacific and South-East Asia regions, highlighting persistent inequalities in cardiovascular health outcomes.

The organisation also reported substantial increases in the burden of other chronic diseases.

According to the report, the risk of dying from diabetes has risen considerably since 2000, particularly in South-East Asia.

Alzheimer’s disease and dementia have also become more prominent.

Dementia rose from the 19th leading cause of death globally in 2000 to the fifth in 2023, while deaths linked to the condition tripled during the period.

Mental health concerns

The WHO also highlighted the growing impact of mental health conditions on global health.

Between 2019 and 2023, the global age-standardised DALY rate increased by approximately 20 per cent for depressive disorders and nearly 45 per cent for anxiety disorders.

Together, depression and anxiety accounted for an estimated 110 million years of healthy life lost through premature death and disability in 2023.

The report further showed changing patterns in drug use disorders across regions.

Between 2000 and 2023, the WHO Region of the Americas recorded the largest increases in mortality risk and healthy life loss associated with drug use disorders, while the Western Pacific region experienced substantial declines.

READ ALSO: Drug-resistant bacterial infections kill one million people annually – WHO

Need for stronger health data systems

Speaking further on the findings, Alani Labrique, Director of WHO’s Department of Data, Digital Health, Analytics and AI, described rising life expectancy as one of public health’s greatest achievements.

However, Mr Labrique noted that the next challenge is ensuring that the additional years people live are spent in good health, while health systems adapt to the changing needs of ageing populations and the growing burden of chronic diseases.

He said the estimates provide countries with evidence on how patterns of death and disease burden are changing over time, helping governments shape health policies, strengthen digital and data infrastructure, and improve their ability to generate insights needed for targeted health interventions.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Trending